Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Will the Next Generation Tissue Biomarkers Market Evolve in Terms of Growth and Size by 2029?
The market size for next generation tissue biomarkers has experienced brisk expansion lately. It is anticipated to surge from $2.68 billion in 2024 to $3.03 billion in 2025, spearheading a compound annual growth rate (CAGR) of 13.1%. This significant growth in the historic period is the result of factors like the mounting demand for personalized medicine, a rise in the application of immunohistochemistry techniques, an amplified need for early disease detection, increased spending on healthcare, a surge in diagnostic imaging technologies, heightened awareness surrounding biomarker-based diagnostics, and a growing emphasis on companion diagnostics.
In the coming years, the anticipated growth in the market size for next generation tissue biomarkers is speculated to trend upwards swiftly, with a projection of reaching $4.89 billion by 2029. The compound annual growth rate (CAGR) is estimated to be at 12.7%. The increase for the predicted duration can be credited to factors like the escalating demand for multiplex biomarker assays, the amplified use of next-generation sequencing, expansion in cancer research investments, applications in digital pathology widening, more use of AI in diagnostics, clinical trials for targeted therapies gaining momentum, and a rise in the accessibility of tissue-based genomic data. Key trends for the forecast period comprise progress in next generation sequencing, the integration of artificial intelligence (AI) in digital pathology, the evolution of advanced mass spectrometry-based proteomics, advancement in ribonucleic acid biomarker detection technologies, and synchronization with cloud based data platforms.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27363&type=smp
What factors are expected to fuel Next Generation Tissue Biomarkers market growth in the coming years?
The surge in demand for customized medical treatment is anticipated to drive the expansion of the next generation tissue biomarkers market. Customized medical treatment is a healthcare tactic that pivots treatment decisions on the individual’s genetic composition, lifestyle, and environmental factors. The increasing acceptance of personalized medicine is due to constant improvements in genomic technologies. These technologies facilitate the creation of highly accurate and individual-specific treatment plans. The popularity of personalized medicine is enhancing the creation of next-generation tissue biomarkers. These biomarkers offer exact and personalized data required to customize treatments based on each patient’s unique tissue pattern. For example, the Personalized Medicine Coalition, a non-profit organization based in the US, stated in February 2024 that the FDA sanctioned 16 new personalized treatments for patients with rare diseases in 2023. This represented an increase from 2022 when six were approved. The personalized treatments approved in 2023 also encompassed seven medications for cancer and three for other diseases and health conditions. As a result, the escalating demand for personalized medicine is fuelling the evolution of the next generation tissue biomarkers market.
What Are The Key Findings From The Segmentation Analysis Of The Next Generation Tissue Biomarkers Market?
The next generation tissue biomarkers market covered in this report is segmented
1) By Type: Genomic Biomarkers, Proteomic Biomarkers, Epigenetic Biomarkers, Transcriptomic Biomarkers, Metabolomic Biomarkers
2) By Technology: Immunohistochemistry, Next-Generation Sequencing, Mass Spectrometry (Ms)-Based Proteomics, Spatial Biology Platforms, Digital Pathology And Artificial Intelligence Analysis, Other Technologies
3) By Application: Oncology, Companion Diagnostics, Drug Discovery And Development, Neurology, Other Applications
4) By End Use: Hospitals And Reference Labs, Pharma And Biotech Companies, Academic And Research Institutes, Contract Research Organizations
Subsegments:
1) By Genomic Biomarkers: Single Nucleotide Polymorphisms, Copy Number Variations, Gene Fusions
2) By Proteomic Biomarkers: Protein Expression Levels, Post-Translational Modifications, Protein-Protein Interactions
3) By Epigenetic Biomarkers: Histone Modification Patterns, Chromatin Remodeling Biomarkers, Non-Coding Ribonucleic Acid Regulation
4) By Transcriptomic Biomarkers: Long Non-Coding Ribonucleic Acids, Circular Ribonucleic Acids, Alternative Splicing Variants
5) By Metabolomic Biomarkers: Lipid Profiles, Amino Acid Signatures, Organic Acids
Which Trends Are Expected To Shape The Future Of The Next Generation Tissue Biomarkers Market?
Predominant corporations in the next generation tissue biomarkers sector are prioritizing the enhancement of advanced solutions such as genomic-based diagnostic assays and sequencing solutions. These initiatives aim to improve the precision, speed, and customization of cancer diagnosis and treatment procedures. Genomic-based diagnostic assays and sequencing solutions encompass tools and techniques that scrutinize genetic data to pinpoint disease-related biomarkers, facilitating more accurate and individualized diagnostics and treatment plans. For instance, in August 2024, biotechnology company Illumina Inc. based in the US received FDA endorsement for its TruSight Oncology Comprehensive test, and two adjunct diagnostics, to quickly align cancer patients with targeted treatments. This test screens over 500 genes from a single tissue specimen, thereby ensuring accurate treatment choices for numerous solid tumors. It introduces an automatic detection of biomarkers and facilitates round-the-clock deployment, remarkably lowering turnaround periods and boosting clinical productivity. This represents a contemporary methodology to streamline cancer diagnostics within a regulatory structure.
What Are The Most Active Companies In The Next Generation Tissue Biomarkers Market Today?
Major companies operating in the next generation tissue biomarkers market are Roche Diagnostics, Thermo Fisher Scientific Inc., LabCorp., Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Bio-Techne Corporation, Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., NanoString Technologies Inc., PathAI Inc., Biocartis Group NV, Personalis Inc., Ultivue Inc., Indica Labs Inc., Strata Oncology Inc., Genialis Inc., Alida Biosciences Inc., and Biofidelity Ltd.
Get The Full Report Here:
Which Regional Markets Are Attracting The Most Investment In Next Generation Tissue Biomarkers?
North America was the largest region in the next generation tissue biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation tissue biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=27363&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model